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Renal transplantation improves survival and quality of life for most patients who require renal replacement therapy, and is usually con-
sidered the treatment of choice for these patients.1 In 
the context of newly introduced immunosuppressive 
agents, the practice of organ transplantation has dra-
matically improved in the recent decades and several 
patients that have escaped the short-term life-threat-
ening complications of the procedure have remained in 
the transplant population. However, these surprising 
achievements were concomitant with new obstacles as-
sociated with newly emerged long-term post-transplant 
complications. Occurring in about 1% of kidney trans-
plant patients, post-transplantation lymphoprolifera-
tive disorder (PTLD) is an entity presenting with a 
usually non-benign proliferation of lymphoid tissues 
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BACKGROUND AND OBJECTIVES: Allograft involvement can occur in some renal transplant recipients who 
develop post-transplant lymphoproliferative disorders (PTLD). We aimed to find indications and/or contraindica-
tions for nephrectomy in renal allograft PTLD based on an outcome analysis of previous reports.
DESIGN AND SETTING: A comprehensive search of Pubmed and Google scholar was performed to find reports 
of different treatment strategies addressing PTLD occurring within the allograft after renal transplantation.
PATIENTS AND METHODS: Patients who underwent nephrectomy due to kidney allograft localization by PTLD 
were categorized as the case group, and renal recipients with kidney PTLD for whom nonsurgical treatment 
modalities were used served as controls.
 RESULTS: Survival analysis demonstrated that patients with renal allograft involvement who underwent allograft 
nephrectomy had a significantly better outcome compared to patients for whom a non-surgical approach was 
used (P=.03). In patients with disseminated PTLD, nephrectomy was not useful (P>.1). Patients with simultane-
ous kidney and lung complications by PTLD benefitted from nephrectomy. 
CONCLUSIONS: We found that patients with renal graft complication with disseminated PTLD do not benefit 
from nephrectomy, which can be considered the only contraindication. However, some particular PTLD co-
localizations were not as likely to adversely affect the benefit of nephrectomy in these patients, and these can be 
considered indications for the procedure. Future multicenter studies are needed to confirm our results.
both in the lymph nodes and extranodal tissues; rep-
resenting one of the most ominous complications of all 
types of organ transplantations.2-5 
PTLD is a very prevalent post-transplant malignan-
cy with a prevalence rate of over 10 to 100 fold greater 
than the normal population. It is a multi-factorial disor-
der that is usually considered a life-threatening compli-
cation. Several factors play roles in the prevalence and 
characteristics of the PTLD. The type of organ trans-
planted is of upmost relevance, with the lowest preva-
lence rate in renal recipients (0.8%-2%);6,7 it is gener-
ally thought that PTLD has a better outcome in renal 
recipients compared to recipients of some other types 
of organs such as heart and lung.8 PTLDs are also in 
the differential diagnosis for acute rejection when they 
occur within the allograft.9,10 We believe that the rel-
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evance of allograft complication by the PTLD in renal 
transplant recipients might be higher than other disease 
localizations due to its impact on the graft function 
and most importantly on the survival of the allograft. 
Moreover, the early graft function deterioration fre-
quently seen in these patients can lead to an early di-
agnosis of the disease in its preliminary stages, leading 
to significant improvement in patient survival. Several 
physicians suggest allograft nephrectomy as the treat-
ment of choice in PTLD complicating the graft, claim-
ing that the procedure prevents further progression of 
the disease. However, this treatment strategy is associ-
ated with an extremely unfavorable consequence: losing 
kidney graft function and returning to dialysis, which is 
probably not a favorite choice for the recipients. On the 
other hand, there is no guarantee that the disease will 
be restrained and completely cured. Moreover, one may 
assume that there might be better choices of treatment, 
but with a comparable patient outcome with no need 
to remove the renal graft. In this study, we tried to col-
lect data on PTLD patients who had kidney allograft 
involvement and compared outcomes of their treatment 
modalities with special emphasis on nephrectomy, aim-
ing to find potential indications and/or contraindica-
tions for nephrectomy in these patients.
PATIENTS AND METHODS
A comprehensive search of Pubmed and Google 
scholar was performed for reports of lymphoprolifera-
tive disorders occurring within the allograft after renal 
transplantation. Keywords used for this purpose were 
“lymphoproliferative disorders + renal transplanta-
tion + nephrectomy” “PTLD + renal transplantation 
+ graft involvement” “PTLD + renal allograft involve-
ment + nephrectomy” “lymphoproliferative disorders + 
renal allograft involvement”. When full text of an article 
was unavailable, an email was sent to correspondent 
authors requesting the article. Only studies with data 
on each individual patient was included. Patients who 
underwent nephrectomy due to kidney allograft local-
ization by PTLD were categorized as the case group, 
and renal recipients with kidney PTLD for whom oth-
er treatment modalities were used served as controls. 
A standard questionnaire was developed to collect data 
from different published studies. Finally, data from 
23 previously published studies from various coun-
tries6,11-32 were included in the analysis. All patients 
were recipients of renal transplants. The time between 
transplantation and PTLD onset was defined as the pe-
riod between the graft and the first signs of PTLD or 
diagnosis, based on the studies. 
Overall 44 recipients of renal allograft were included 
in the analysis. Because data for this study came from 
various studies with various designs, we were not able 
to derive all data we needed. Renal allograft was the 
malignancy involvement site in all the patients. Twenty-
two (50%) of them undergone nephrectomy while the 
remaining 50% of patients received other therapies, if at 
all. Disseminated lymphomas were considered to exist 
if reported by author, or three or more involvement sites 
were reported for the patient excluding different lymph 
node sites. Multi-organ PTLD was considered to exist 
if documented by author, and/or two or more PTLD 
sites were reported by the authors for the PTLD ex-
Table 1. Characteristics of the study patients with renal allograft PTLD disease.
Characteristics Number of patients
Age, mean and SD (y) 36.3 (19.3) 39
Pediatric (%) 9 (23.1) 39
Gender male (%) 25 (69.4) 36
Months to PTLD (mo) 20.7 (30.4) 42
Early onset (%) 26 (61.9) 42
Living donor (vs. cadaver) 6 (31.6) 19
Histopathologic 
morphology
Early lesion 0
28
Polymorphic 12 (42.9)
Monomorphic 11 (39.3)
Hodgkin disease 5 (11.4)
Monoclonal (%) 2 (18.2) 11
Cell type (B cell) 17 (81) 21
Immunosuppression 
basisa Basis 1 (3.8)
26+MMF 3 (11.5)
+ azathioprine 20 (76.9)
+ FK-506 2 (7.7)
Multi-organ involvement 
(%) 19 (52.8) 36
Disseminated disease (%) 10 (32.3) 31
Malignancy response to 
treatment 21 (75) 28
Death due to PTLD 8 (20.5) 39
Treatment strategies
Nephrectomy 22 (50) 44
Radiotherapy 2 (18.2) 11
Alfa-interferon 2 (20) 10
Chemotherapy 9 (60) 15
aall of the regimens included cyclosporine and corticosteroids
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cluding lymph node sites. According to the these cri-
teria, disseminated PTLD was reported in 10 (32.3%; 
13 unreported) patients; and multi-organ disease was 
available in 19 (52.8%; 8 unreported) patients. Epstein-
Barr virus (EBV) serologic status was documented 
in 27 (61.4%) patients; 22 (81.5%) were seroposi-
tive. Response to treatment was defined as any favor-
able change in the malignancy measures as well as the 
patients’ clinical condition. Data on PTLD response 
to treatment was reported for 21 (47.7%) patients of 
whom 18 (85.7%) patients responded to anti-malig-
nancy treatment. To enhance our data we developed 
new criteria for defining remission: death within the 
first post diagnosis month was considered no-remis-
sion; still living after the 24th post-transplant month 
was considered in remission. With these criteria, 21 
(75%) patients were responders to therapy and 7 (25%) 
were non-responders. Overall, 10 (23.8%) patients died 
during their follow-up period. Death due to PTLD was 
reported in 6 (60%). 
At lymphoma diagnosis, all patients were on im-
munosuppressive regimens consisting of varying com-
binations of azathioprine, prednisone, cyclosporine, 
mycophenolate mofetil, and antithymocyte/lympho-
cyte globulin (ATG/ALG) and OKT3. More and 
less, a rather uniform approach was used to manage all 
PTLD patients in the included reports. On diagnosis 
of PTLDs, the first step in almost all reports was to de-
crease or discontinue immunosuppressive therapy; dif-
ferent regimens of chemotherapy with or without sur-
gical interventions were also used for some of patients. 
Software used for data analyses was SPSS v.17.0 
(IBM Corp, Armonk, NY, USA). Statistical differences 
between subgroups were performed using the chi-
square and Fisher exact tests for proportions and the 
t test for continuous data. Survival analysis was done 
with life tables and Kaplan-Meier methods and the log-
rank test. All statistical tests were performed at the .05 
significance level. A P value of .1 was also considered 
relevant.
RESULTS
Overall, 44 patients with lymphoproliferative disor-
ders after renal transplantation were entered into the 
analysis. There were 25 (69.4%) males and 11 (30.6%) 
female patients (8 unreported). Mean (standard devia-
tion) age at diagnosis of PTLD was 36.3 (19.3) years 
(median: 33.5; range: 1.3 to 74). The mean interval be-
tween transplantation and the diagnosis of PTLD was 
20.7 (30.4) (median: 24; range: 0.2 to 250) months 
whereas follow-up time after diagnosis of PTLD was 
29.3 (31.8) (median: 32.5; range: 0.1 to 122) months. 
For patients with a single disease site (only renal graft 
PTLD) the these measures were 36.7 (21) (median: 
32; range: 1.3 to 72), 14.3 (21.9) (median: 19.5; range: 
1 to 96) and 44.9 (36.7) (median: 39; range: 0.6 to 
121.5), respectively. 
Characteristics of the study patients are summa-
rized in Table 1. One and 5-year survival rates for 
renal recipients with graft PTLD were both 88% for 
patients who underwent nephrectomy, while they were 
64% and 43% for the control group. Survival analysis 
Figure 1. Survival curves of renal recipients with kidney localization for PTL.
Figure 2. Survival curves of renal recipients with allograft PTLD and multi-organ disease 
who undergone nephrectomy or other treatments. 
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demonstrated that patients with renal allograft in-
volvement who had undergone allograft nephrectomy 
for managing their disease had a significantly better 
outcome compared to patients with the same patients 
for whom other treatment strategies were employed 
(P=.03; Figure 1). However, when death due to PTLD 
(excluding other reasons) was used as the end point no 
significant difference was observed (P=.19). On the 
other hand, when we analyzed data of patients with 
multi-organ disease, nephrectomy showed no signifi-
cant survival advantage compared to other treatments 
(Figure 2). Histological patterns including clonality 
and morphology were not different between the two 
groups. However, renal recipients who had dissemi-
nated disease alongside the graft PTLD, less likely had 
undergone nephrectomy, but multi-organ disease (as 
defined in the methods) was comparable between the 
groups. No other difference was found regarding other 
organs involvement frequency between the two groups 
(Table 2). 
We reanalyzed our data to find whether nephrecto-
my can improve the outcome of renal recipients when 
their graft is involved by PTLD when other organs were 
simultaneously complicated by the neoplasm. First we 
entered patients with disseminated disease into the 
analysis. The log-rank test showed no beneficial effect 
for nephrectomy, when performed in renal recipients 
with three or more PTLD involvement sites (P=.583; 
Figure 3). Then we only included patients who had 
developed graft and respiratory system PTLD involve-
ment simultaneously. We found that nephrectomy re-
sulted in a relevant improvement in the outcomes, but 
a significance level was not achieved (P=.09; Figure 4). 
Data was again analyzed for patients with graft and 
liver PTLD involvement simultaneously, but there was 
no advantage for nephrectomy in the outcome (P=.21; 
Figure 5).
DISCUSSION
Allograft involvement by PTLD is an important lo-
calization for the neoplasm because it directly affects 
graft survival alongside other associated morbidities 
Table 2. Frequency of the organs involved by PTLD in 33 renal 
transplant recipients with graft PTLD. 
Involved organs Frequency (%)
Genitalia 1 (3)
Spleen 2 (6)
Colon 1 (3)
Adrenal 1 (3)
Liver 9 (27)
Small intestine 1 (3)
Respiratory system 6 (18.2)
Bone marrow 2 (6)
Skin 2 (6)
Heart 2(6)
Figure 3. Effect of nephrectomy on renal recipients outcome when graft PTLD and 
disseminated disease exists (three or more organs complicated).
Figure 4. Effect of nephrectomy on the outcome of renal recipiets whose allograft is 
involved by PLTD simultaneous with respiratory system.
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and mortalities. On the other hand, due to its effect 
on graft function,33,34 PTLD simulates graft rejection35 
and therefore, all renal recipients with graft function de-
terioration should be evaluated for a potential PTLD 
development. Early evaluation can lead to earlier diag-
nosis of the disease, and therefore a better outcome;36 
although contrary reports also exist.37 
Some authors have proposed that allograft involve-
ment by PTLD is a frequent condition, although de-
spite a very comprehensive search, we only found 44 
cases. None of the transplant centers in Iran with larg-
est renal transplant patient population had cases of re-
nal graft PTLD. One reason for this observation can be 
an underestimate in diagnosis, mainly due to imperfect 
evaluation of patients who come with graft dysfunction, 
and empiric treatment without histopathological evalu-
ations. Being of high or low frequency, in the current 
study we aimed to evaluate how often nephrectomy of 
the affected kidney graft by the PTLD enhanced the 
outcome and investigated potential indications for the 
surgical procedure.
Overall, in this study we found that patients with 
renal graft PTLD who had undergone nephrecto-
my had a superior long-term outcome than patients 
whose complicated graft was not removed (Figure 1). 
Nevertheless, this finding does not demonstrate that 
nephrectomy of the PTLD complicated kidney pro-
vides a survival advantage over other treatments. One 
may assume that physicians are more likely to choose 
nephrectomy in patients with more favorable condi-
tions whose PTLD lesions have not widely spread, 
than in patients with ominous conditions. Considering 
this logical criticism, we reanalyzed our data for pa-
tients with disseminated PTLD to determine whether 
nephrectomy provides a better outcome for those with 
disseminated disease. The log-rank test showed that re-
nal recipients with disseminated PTLD do not benefit 
from renal graftectomy while their graft is also compli-
cated by the disease. This is a very significant finding, 
alerting us to avoid the surgical procedure whenever 
we observed a graft PTLD complication, thus provid-
ing an indication for graftectomy. After concluding 
that disseminated PTLD can be a contraindication 
for nephrectomy in patients with renal graft PTLD 
(RGPTLD), we re-examined to what extent nephrec-
tomy can be considered for treatment of RGPTLD pa-
tients. Data was analyzed for patients who had multi-
organ PTLD (according to the definition in the meth-
ods section), but again, no statistically difference was 
found between patients by treatment mode, although 
the figures showed some degrees of disparity. 
Thus, we thought that some specific organs that 
Figure 5. Effect of nephrectomy on the outcome of renal transplant recipients when their 
graft is complicated by PLTD simultaneous with liver.
are simultaneously affected by PTLD in patients with 
multi-organ disease might not alter the outcome of ne-
phrectomy in kidney recipients with graft disease. Data 
was reanalyzed for patients who had simultaneous in-
volvement by different organs alongside the renal graft, 
one by one. Although none of the analyses for differ-
ent organs reached statistical significance, patients who 
had respiratory system involvement relevantly benefited 
from renal graftectomy despite the spread of the dis-
ease, but when the liver was a site of PTLD, no advan-
tage was detected for the surgical procedure.
Potential criticisms of this study are first that data 
was gathered from populations from different stud-
ies with inconsistent approaches. This probably is the 
unique major limitation for this study, leading to sub-
stantially unreported data for some of the study vari-
ables and therefore decreasing the power of our analy-
ses. This limitation was most prominent for special data 
that are not normally reported in studies on PTLD pa-
tients. On the other hand, inclusion criteria used for the 
23 series included into this analysis were diverse; while 
some of the reports were simple series report from indi-
vidual centers, others focused on allograft involvement 
or some other criteria. Because of these inconsistencies 
we are unable to globalize our observations on the in-
cidence or frequencies of some variables in our study 
population. Another limitation of this study associated 
with gathering data from different reports was that re-
sults of different studies were not presented in the same 
way. For example, reports of response to treatment were 
presented dissimilarly. While in one study partial and 
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complete remission, in another only “response to treat-
ment” was used; in others no specific terminology was 
employed. Thus we need new methods to accumulate 
the existing data for analysis. 
In conclusion, we suggest defining some indications 
and contraindications for nephrectomy in renal recipi-
ents who develop graft PTLD. Through this study, we 
found that RGPTLD with disseminated PTLD does 
not benefit from nephrectomy. Also, some particular 
PTLD localizations were likely not to adversely affect 
the beneficial effect of nephrectomy and can be consid-
ered among the indications for the procedure. Further 
studies with prospective approaches are needed for 
a more precise determination of the indications and 
contraindications for nephrectomy in renal recipients 
developing PTLD within their graft. 
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